Novartis today announced that it has entered into an agreement to acquire Excellergy, Inc., a private biotech company developing next-generation anti-IgE therapies for IgE-driven diseases. The proposed acquisition adds Exl-111, a half-life extended, high-affinity anti-IgE antibody in Phase 1. The acquisition builds on deep Novartis expertise in IgE biology and a long-standing presence in allergic disease. Under the terms of the agreement, Novartis will pay up to USD 2 billion in upfront and milestone payments to acquire Excellergy.
Read the full article: Novartis Agrees to Acquire Excellergy, Inc., Building on Allergy Leadership with Next-Generation Anti-IgE Innovation //
Source: https://www.globenewswire.com/news-release/2026/03/27/3263554/0/en/Novartis-agrees-to-acquire-Excellergy-Inc-building-on-allergy-leadership-with-next-generation-anti-IgE-innovation.html?_gl=1*11gjnrr*_up*MQ..*_ga*MzQ4NjcwMTg3LjE3NzQ1OTU2MzQ.*_ga_B6167QB2TF*czE3NzQ1OTU2MzQkbzEkZzAkdDE3NzQ1OTU2MzQkajYwJGwwJGgw*_ga_ERWPGTJ5X8*czE3NzQ1OTU2MzQkbzEkZzAkdDE3NzQ1OTU2MzQkajYwJGwwJGgw